ArticlePloS one2013
The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 82 citations in OpenAlex.
- Article
- Structural atlas of Pakpunavirus P7-1 reveals determinants of virion stability and genome ejection.Communications biology · 2026Article
- Article
- Structural atlas ofbioRxiv : the preprint server for biology · 2025Article
- R-pyocins as targeted antimicrobials against Pseudomonas aeruginosa.npj antimicrobials and resistance · 2025Review
- Isolation, Characterization, and Genomic Analysis of Bacteriophages AgainstMicroorganisms · 2025Article
- Isolation and characterization of new lytic bacteriophage PSA-KC1 against Pseudomonas aeruginosa isolates from cystic fibrosis patients.Scientific reports · 2025Article
- Pseudomonas aeruginosa maintains an inducible array of novel and diverse prophages over lengthy persistence in cystic fibrosis lungs.FEMS microbiology letters · 2025Article
- Synthesis of Headful Packaging Phages Through Yeast Transformation-Associated Recombination.Viruses · 2024Article
- Molecular and bacteriological investigations for the co-existence CRISPR/Cas system and β-lactamases of types extended-spectrum and carbapenemases in Multidrug, extensive drug and Pandrug-ResistantSaudi journal of biological sciences · 2024Article
- Phage therapy: breathing new tactics into lower respiratory tract infection treatments.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Review
- Long-Term Effectiveness of Engineered T7 Phages Armed with Silver Nanoparticles AgainstInternational journal of nanomedicine · 2024Article
- A novel lytic phage exhibiting a remarkable in vivo therapeutic potential and higher antibiofilm activity against Pseudomonas aeruginosa.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- Current knowledge in the use of bacteriophages to combat infections caused by Pseudomonas aeruginosa in cystic fibrosis.Folia microbiologica · 2023Review
- Bacteriophages as Biotechnological Tools.Viruses · 2023Review
- Prevalence and analysis of CRISPR/Cas systems in Pseudomonas aeruginosa isolates from Greece.Molecular genetics and genomics : MGG · 2022Article
- Engineered Bacteriophages Containing Anti-CRISPR Suppress Infection of Antibiotic-Resistant P. aeruginosa.Microbiology spectrum · 2022Article
- Bacteriophage therapy in aquaculture: current status and future challenges.Folia microbiologica · 2022Review
- Isolation and characterization of lytic bacteriophages againstIranian journal of microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phage therapy may become a complement to antibiotics in the treatment of chronic Pseudomonas aeruginosa infection. To design efficient therapeutic cocktails, the genetic diversity of the species and the spectrum of susceptibility to bacteriophages must be investigated. Bacterial strains showing high levels of phage resistance need to be identified in order to decipher the underlying mechanisms. Here we have selected genetically diverse P. aeruginosa strains from cystic fibrosis patients and tested their susceptibility to a large collection of phages. Based on plaque morphology and restriction profiles, six different phages were purified from "pyophage", a commercial cocktail directed against five different bacterial species, including P. aeruginosa. Characterization of these phages by electron microscopy and sequencing of genome fragments showed that they belong to 4 different genera. Among 47 P. aeruginosa strains, 13 were not lysed by any of the isolated phages individually or by pyophage. We isolated two new phages that could lyse some of these strains, and their genomes were sequenced. The presence/absence of a CRISPR-Cas system (Clustered Regularly Interspaced Short Palindromic Repeats and Crisper associated genes) was investigated to evaluate the role of the system in phage resistance. Altogether, the results show that some P. aeruginosa strains cannot support the growth of any of the tested phages belonging to 5 different genera, and suggest that the CRISPR-Cas system is not a major defence mechanism against these lytic phages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.